{"id":"lhrh-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Decreased libido"},{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LhRH antagonists competitively bind to GnRH receptors in the pituitary gland, immediately blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to rapid suppression of testosterone in males and estrogen in females, without the initial testosterone surge seen with GnRH agonists. The mechanism is used therapeutically to suppress sex hormone-dependent conditions.","oneSentence":"LhRH antagonists block luteinizing hormone-releasing hormone receptors to suppress gonadotropin secretion and reduce sex hormone production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:08.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (hormone-sensitive)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT04705038","phase":"NA","title":"Effect of Education on Treatment Decision Making for Patients With Prostate Cancer on Chronic Hormone Treatments","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2020-12-18","conditions":"Prostate Cancer","enrollment":101},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT02871167","phase":"NA","title":"Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2016-12","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT07340827","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)","status":"RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2026-02-05","conditions":"Infertility","enrollment":333},{"nctId":"NCT03419234","phase":"PHASE2","title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2018-04-26","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue","enrollment":223},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT07457164","phase":"PHASE2","title":"A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Antev Ltd.","startDate":"2026-07","conditions":"Advanced Prostate Cancer, GnRH Antagonist","enrollment":40},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":"Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer","enrollment":33},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT05999968","phase":"PHASE1","title":"Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-01-12","conditions":"Prostatic Neoplasms","enrollment":10},{"nctId":"NCT05726292","phase":"PHASE2","title":"A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-01-06","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT06395753","phase":"PHASE2","title":"A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2024-05-23","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":"Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography","enrollment":118},{"nctId":"NCT07394530","phase":"NA","title":"Comparison of IVF Outcomes Between PPOS and Antagonist Protocols in Women With PCOS","status":"RECRUITING","sponsor":"Hanoi General Hospital (Vietnam)","startDate":"2026-01-20","conditions":"Polycystic Ovary Syndrome (PCOS), Female Infertility","enrollment":400},{"nctId":"NCT07212712","phase":"NA","title":"The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2026-04-01","conditions":"Cerebral Blood Flow, Cerebral Blood Flow Regulation, Sex Differences","enrollment":50},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":223},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT05326087","phase":"PHASE3","title":"Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A","status":"NOT_YET_RECRUITING","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2026-06-01","conditions":"Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Polycystic Ovarian Syndrome","enrollment":204},{"nctId":"NCT05568550","phase":"PHASE2","title":"Pembro With Radiation With or Without Olaparib","status":"RECRUITING","sponsor":"Zin W Myint","startDate":"2023-07-27","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07111247","phase":"PHASE4","title":"Insights in Endocervical Mucus Secretion","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-01-02","conditions":"Cervical Mucus","enrollment":15},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":"Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT00309985","phase":"PHASE3","title":"Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2006-09-26","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":790},{"nctId":"NCT05847283","phase":"NA","title":"DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT","status":"RECRUITING","sponsor":"Tam Anh TP. Ho Chi Minh General Hospital","startDate":"2023-06-22","conditions":"Diminished Ovarian Reserve","enrollment":730},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT06613100","phase":"PHASE1","title":"Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-11-25","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT06594926","phase":"PHASE2","title":"Working Out M0 Bipolar Androgen Therapy","status":"RECRUITING","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2024-08-14","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT03541850","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-29","conditions":"PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7","enrollment":92},{"nctId":"NCT02677896","phase":"PHASE3","title":"A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-03-09","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":1150},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT04265053","phase":"EARLY_PHASE1","title":"Human Cerebral Blood Flow Regulation","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2021-04-12","conditions":"Cerebral Arterial Diseases","enrollment":110},{"nctId":"NCT06466486","phase":"PHASE1","title":"An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2024-06-14","conditions":"Fertility","enrollment":310},{"nctId":"NCT06511791","phase":"PHASE1","title":"An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation.","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2024-07-15","conditions":"Infertility","enrollment":106},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT06023602","phase":"NA","title":"Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF","status":"RECRUITING","sponsor":"Northwest Women's and Children's Hospital, Xi'an, Shaanxi","startDate":"2024-02-27","conditions":"Infertility","enrollment":1338},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT03275181","phase":"","title":"Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer","status":"COMPLETED","sponsor":"Kansas State University","startDate":"2017-08-01","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT06390904","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity","enrollment":29},{"nctId":"NCT06379113","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance","enrollment":29},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT01952223","phase":"PHASE3","title":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-12","conditions":"Adenocarcinoma of Prostate, Progression of Prostate Cancer","enrollment":761},{"nctId":"NCT07076719","phase":"","title":"Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-10-01","conditions":"to Evaluate the Feasibility and Accuracy of Using cfDNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for PGD","enrollment":20},{"nctId":"NCT05448547","phase":"PHASE3","title":"Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Sven Löffeler","startDate":"2022-11-04","conditions":"Prostate Cancer","enrollment":980},{"nctId":"NCT03680053","phase":"NA","title":"Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF","status":"TERMINATED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-04-10","conditions":"Infertility, ART","enrollment":220},{"nctId":"NCT04414748","phase":"PHASE3","title":"Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2020-06-10","conditions":"Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Euploid Rate","enrollment":400},{"nctId":"NCT06312670","phase":"PHASE2","title":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Pedro Barata, MD, MSc","startDate":"2024-05-16","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma","enrollment":13},{"nctId":"NCT03703778","phase":"","title":"Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2016-05-22","conditions":"Prostate Cancer","enrollment":300},{"nctId":"NCT03641560","phase":"PHASE4","title":"A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2018-09-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":52},{"nctId":"NCT05263388","phase":"PHASE3","title":"A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2022-07-15","conditions":"Infertility","enrollment":302},{"nctId":"NCT05057546","phase":"PHASE4","title":"Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-11-22","conditions":"Menopause, Estrogen Deficiency, Women","enrollment":55},{"nctId":"NCT06868576","phase":"PHASE3","title":"PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2023-01-03","conditions":"PPOS, GnRH Antagonist, Assisted Reproductive Techniques","enrollment":328},{"nctId":"NCT06812559","phase":"","title":"Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"El Shatby University Hospital for Obstetrics and Gynecology","startDate":"2023-12-01","conditions":"Controlled Ovarian Hyperstimulation, Polycystic Ovarian Syndrome","enrollment":100},{"nctId":"NCT06838520","phase":"","title":"Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":200},{"nctId":"NCT05447208","phase":"PHASE3","title":"Effect of GH on the Blastocyst Euploid Rate in AMA Patients","status":"RECRUITING","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2022-08-01","conditions":"Preimplantation Genetic Testing, Growth Hormone, Age, Parental","enrollment":400},{"nctId":"NCT05166668","phase":"NA","title":"Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2021-11-01","conditions":"Ovarian Stimulation","enrollment":200},{"nctId":"NCT05286554","phase":"PHASE4","title":"Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2022-03-17","conditions":"Female Infertility","enrollment":75},{"nctId":"NCT01994239","phase":"PHASE2","title":"Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2012-12","conditions":"Adenocarcinoma of Prostate","enrollment":120},{"nctId":"NCT03569241","phase":"PHASE2","title":"PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-04-27","conditions":"Prostate Cancer, Prostate Cancer Metastatic, Metastatic Cancer","enrollment":196},{"nctId":"NCT01957436","phase":"PHASE3","title":"A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-11-13","conditions":"Metastatic Prostate Cancer","enrollment":1173},{"nctId":"NCT06655259","phase":"PHASE2","title":"Combination of TURP and Standard Systemic Therapy for MPCa","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-09-21","conditions":"Metastatic Prostate Cancer","enrollment":200},{"nctId":"NCT05767086","phase":"NA","title":"Comparison of 3 Different Protocols for Preventing Premature Ovulation in Ovarian Stimulation Cycles","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-03-15","conditions":"Infertility","enrollment":297},{"nctId":"NCT02758431","phase":"NA","title":"Cardiovascular Outcomes of Low Testosterone","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-07-01","conditions":"Hypogonadism","enrollment":232},{"nctId":"NCT03777982","phase":"PHASE3","title":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-04-20","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT00702234","phase":"","title":"Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-02-15","conditions":"Pregnancy, Neonates","enrollment":268},{"nctId":"NCT02890082","phase":"PHASE2","title":"Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT06396390","phase":"PHASE4","title":"Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nesta Clinic","startDate":"2024-08-01","conditions":"IVF, Fertility Issues, Infertility","enrollment":152},{"nctId":"NCT06481696","phase":"NA","title":"Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility","status":"RECRUITING","sponsor":"Andros Day Surgery Clinic","startDate":"2024-06-01","conditions":"Unexplained Infertility","enrollment":90},{"nctId":"NCT06264882","phase":"PHASE4","title":"Cardiometabolic Consequences of the Loss of Ovarian Function","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-06-01","conditions":"Menopause, Estrogen Deficiency, Aging","enrollment":100},{"nctId":"NCT00702845","phase":"PHASE3","title":"To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-12-28","conditions":"Infertility","enrollment":397},{"nctId":"NCT00696878","phase":"PHASE3","title":"Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09-26","conditions":"In Vitro Fertilization","enrollment":682},{"nctId":"NCT03809429","phase":"PHASE3","title":"Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)","status":"COMPLETED","sponsor":"Ferring Pharmaceuticals","startDate":"2019-04-29","conditions":"Infertility, Female","enrollment":437},{"nctId":"NCT04487925","phase":"PHASE4","title":"Controlled Ovarian Stimulation Versus Modified Natural Cycles in Poor Responders","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-01-25","conditions":"Ovarian Reserve, Poor Responders, IVF","enrollment":208},{"nctId":"NCT03358563","phase":"EARLY_PHASE1","title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-17","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT06297564","phase":"NA","title":"Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Assisted Reproductive Treatments","status":"COMPLETED","sponsor":"New Valley University","startDate":"2022-09-01","conditions":"Progesterone Primed Endometrial Protocol, Gonadotropin Releasing Hormone Antagonist Protocol, Assisted Reproductive Treatments","enrollment":40},{"nctId":"NCT01712763","phase":"PHASE3","title":"Degarelix in the Treatment of Endometriosis Recurrence","status":"COMPLETED","sponsor":"Centre for Endocrinology and Reproductive Medicine, Italy","startDate":"2012-11","conditions":"Endometriosis","enrollment":360},{"nctId":"NCT04989348","phase":"NA","title":"Euploid Rate of Blastocyst Derived From PPOS VS Antagonist Protocol","status":"COMPLETED","sponsor":"Shanghai First Maternity and Infant Hospital","startDate":"2021-08-04","conditions":"IVF","enrollment":240},{"nctId":"NCT04671966","phase":"PHASE4","title":"Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction","status":"UNKNOWN","sponsor":"The University of Texas at Arlington","startDate":"2018-09-13","conditions":"Heart Diseases, Left Ventricular Dysfunction","enrollment":100},{"nctId":"NCT02995330","phase":"PHASE1","title":"Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-09","conditions":"Prostate Cancer","enrollment":3},{"nctId":"NCT03899077","phase":"PHASE2","title":"Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP","status":"UNKNOWN","sponsor":"Cancer Research Antwerp","startDate":"2019-04-05","conditions":"Cancer of Prostate","enrollment":202},{"nctId":"NCT04327934","phase":"EARLY_PHASE1","title":"Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome","status":"TERMINATED","sponsor":"Yale University","startDate":"2017-12-01","conditions":"Polycystic Ovary Syndrome, Hypertension","enrollment":28},{"nctId":"NCT06212102","phase":"PHASE2","title":"Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation","status":"NOT_YET_RECRUITING","sponsor":"Bedaya Hospital","startDate":"2024-02","conditions":"Infertility","enrollment":120},{"nctId":"NCT04043520","phase":"PHASE4","title":"Bioenergetic Effects of Aging and Menopause (BEAM)","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2019-09-24","conditions":"Menopause, Obesity, Abdominal, Aging","enrollment":57},{"nctId":"NCT02312089","phase":"PHASE4","title":"GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-08-07","conditions":"Infertility","enrollment":200},{"nctId":"NCT04724486","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI","status":"COMPLETED","sponsor":"Damascus University","startDate":"2020-08-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50},{"nctId":"NCT04724343","phase":"PHASE4","title":"Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.","status":"COMPLETED","sponsor":"Damascus University","startDate":"2019-12-22","conditions":"In Vitro Fertilization, Intracytoplasmic Sperm Injection, Infertility","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":263,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Degarelix 120 MG"],"phase":"marketed","status":"active","brandName":"LhRH-antagonist","genericName":"LhRH-antagonist","companyName":"Turku University Hospital","companyId":"turku-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LhRH antagonists block luteinizing hormone-releasing hormone receptors to suppress gonadotropin secretion and reduce sex hormone production. Used for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}